Interpreting and Applying Risk Assessment and Cardiovascular Outcomes Trial Data – Where Do We Go From Here?

1.00 CME
60 MINS
$0 FEE
SAVE
cardiology

Overview

Provider Statement

This continuing medical education activity is provided by Vindico Medical Education.


Support Statement

This activity is supported by an educational grant from Amarin Pharma Inc.  


Activity Description

In the United States, cardiovascular (CV) disease is the leading cause of death, claiming more than 600,000 lives annually. Optimal management of CV risk requires the integrated effort of multidisciplinary specialists who are current on the latest guidelines and therapeutic strategies to reduce CV risk. However, providers lack knowledge of new therapies that have reduced CV risk and how to use them. New findings from CV outcomes trials have resulted in cardiologists rethinking their current therapeutic regimens. In this live educational activity, expert physicians will examine CV risk assessment and important outcomes trials.


Target Audience

The intended audience for the activities is cardiologists and other health care professionals involved in the management of patients with cardiovascular risk.


Learning Objective(s)

Upon successful completion of this activity, participants should be better able to:

  • Utilize evidence-based risk assessment tools to determine residual risk in patients with, or at high risk for, atherosclerotic cardiovascular disease (ASCVD).
  • Assess the results from recent cardiovascular risk outcomes trials and their potential impact to clinical practice. 
  • Incorporate clinical findings from major cardiovascular outcomes trials to improve outcomes in patients who are already on statin therapy but remain at risk for cardiovascular events.

Activity Chair

Sergio Fazio, MD, PhD
The William and Sonja Connor Chair of Preventive Cardiology
Professor of Medicine, Physiology and Pharmacology
Director, Center for Preventive Cardiology
Knight Cardiovascular Institute
Oregon Health & Science University
Portland, OR


Faculty

Deepak L. Bhatt, MD, MPH, FAHA
Executive Director of Interventional Cardiovascular Programs 
Brigham and Women’s Hospital Heart and Vascular Center 
Professor of Medicine 
Harvard Medical School 
Boston, MA

Amit Khera, MD, MSc, FAHA
Professor of Medicine
Director, Preventive Cardiology
Dallas Heart Ball Chair in Hypertension and Heart Disease
Division of Cardiology
UT Southwestern Medical Center
President, American Society for Preventive Cardiology
Dallas, TX

Ann Marie Navar, MD, PhD
Faculty Innovations Director &
Assistant Professor of Medicine
Duke Clinical Research Institute
Duke School of Medicine
Durham, NC


Reviewer

Ronald A. Codario, MD, EMBA, FACP, FNLA, RPVI, CHCP


Accreditation

Vindico Medical Education is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.


Credit Designation

Vindico Medical Education designates this enduring material for a maximum of 1.0 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity. 

This enduring material is approved for 1 year from the date of original release, March 5, 2020, to March 4, 2021.


How to Participate in this Activity and Obtain CME Credit

To participate in this CME activity, you must read the objectives, answer the pretest questions, view the content, and complete the CME posttest and evaluation. Provide only one (1) correct answer for each question. A satisfactory score is defined as answering 2 out of 3 posttest questions correctly. Upon receipt of the completed materials, if a satisfactory score on the posttest is achieved, Vindico Medical Education will issue an AMA PRA Category 1 Credit(s)™ Certificate.


MIPS Qualifying Activity


Completion of this accredited CME activity meets the expectations of an Accredited Safety or Quality Improvement Program (IA_PSPA_28) for the Merit-based Incentive Payment Program (MIPS). Participants who successfully complete the activity and its performance assessment will receive printable documentation of successful completion for MIPS self-reporting.
To meet the criteria for improvement activities in the Merit-Based Incentive Payment System (MIPS) of QPP, accredited CME providers need to implement activities that:

  • address a quality or safety gap that is supported by a needs assessment or problem analysis, or support the completion of such a needs assessment as part of the activity;
  • have specific, measurable aim(s) for improvement;
  • include interventions intended to result in improvement;
  • include data collection and analysis of performance data to assess the impact of the interventions; and
  • define meaningful clinician participation in their activity, describe the mechanism for identifying clinicians who meet the requirements, and provide participant completion information.

Disclosures

In accordance with the Accreditation Council for Continuing Medical Education’s Standards for Commercial Support, all CME providers are required to disclose to the activity audience the relevant financial relationships of the planners, teachers, and authors involved in the development of CME content. An individual has a relevant financial relationship if he or she has a financial relationship in any amount occurring in the past 12 months with a commercial interest whose products or services are discussed in the CME activity content over which the individual has control. Relationship information appears below.

The authors disclose that they do have significant financial interests in any products or class of products discussed directly or indirectly in this activity, including research support.

Activity Chair and Faculty report the following relationship(s)

Deepak L. Bhatt, MD, MPH, FAHA
Contracted Research: Abbott Medical Optics, Amarin, Amgen, AstraZeneca, Bayer, Boehringer Ingelheim, Bristol-Myers Squibb, Chiesi, CSL Behring, Eisai, Ethicon, Forest Laboratories, Idorsia, Ironwood, Ischemix, Lilly, Medtronic, Pfizer, PhaseBio, Regeneron, Roche, Sanofi-Aventis, Synaptic, The Medicines Company

Sergio Fazio, MD, PhD
Consulting Fee: Amarin, Amgen, AstraZeneca, Esperion, Novartis

Amit Khera, MD, MSc, FAHA
No relevant financial relationships to disclose.

Ann Marie Navar, MD, PhD
Contracted Research: Amarin, Amgen, Janssen, Regeneron, Sanofi
Consulting Fee: Amarin, Amgen, AstraZeneca, Janssen, Novo Nordisk, Regeneron, Sanofi

Reviewer reports the following relationship(s)

Ronald A. Codario, MD, EMBA, FACP, FNLA, RPVI, CHCP
No relevant financial relationships to disclose. 

Vindico Medical Education staff report the following relationship(s)

No relevant financial relationships to disclose.

Signed disclosures are on file at Vindico Medical Education, Office of Medical Affairs and Compliance.


Unlabeled and Investigational Usage

The audience is advised that this continuing medical education activity may contain references to unlabeled uses of US Food and Drug Administration (FDA)-approved products or to products not approved by the FDA for use in the United States. The faculty members have been made aware of their obligation to disclose such usage. All activity participants will be informed if any speakers/authors intend to discuss either non–FDA-approved or investigational use of products/devices.


Copyright Statement

Created and published by Vindico Medical Education, 6900 Grove Road, Building 100, Thorofare, NJ 08086-9447. Telephone: 856-994-9400; Fax: 856-384-6680. Printed in the USA. Copyright © 2020 Vindico Medical Education. All rights reserved. No part of this publication may be reproduced without written permission from the publisher. The material presented at or in any of Vindico Medical Education continuing medical education activities does not necessarily reflect the views and opinions of Vindico Medical Education. Neither Vindico Medical Education nor the faculty endorse or recommend any techniques, commercial products, or manufacturers. The faculty/authors may discuss the use of materials and/or products that have not yet been approved by the US Food and Drug Administration. All readers and continuing education participants should verify all information before treating patients or utilizing any product.


CME Questions?

Contact us at cme@vindicoCME.com